-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Broad Pharmaceutical (China)'s norepinephrine bitartrate injection was approved as a supplementary application, making it the first company to have reviewed the product
.
According to data from Menet.
com, the sales of terminal norepinephrine bitartrate injection in public medical institutions in China have grown rapidly in recent years.
After breaking through more than 1 billion yuan in 2019, it will hit a new high in 2020
.
There are 7 manufacturers of this product.
Among them, Yuanda Pharmaceutical (China) has the largest market share, exceeding 70%
.
At present, Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval, and Hefei Yifan Biopharmaceuticals are under review and approval for listing applications submitted in generic 3 categories.
After approval, they will be deemed as over-evaluated
.
.
According to data from Menet.
com, the sales of terminal norepinephrine bitartrate injection in public medical institutions in China have grown rapidly in recent years.
After breaking through more than 1 billion yuan in 2019, it will hit a new high in 2020
.
There are 7 manufacturers of this product.
Among them, Yuanda Pharmaceutical (China) has the largest market share, exceeding 70%
.
At present, Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval, and Hefei Yifan Biopharmaceuticals are under review and approval for listing applications submitted in generic 3 categories.
After approval, they will be deemed as over-evaluated
.
Data show that norepinephrine bitartrate injection can be used to treat hypotension caused by acute myocardial infarction, cardiopulmonary bypass, etc.
, for shock, hypotension or hypotension after pheochromocytoma resection due to hypovolemia
.
, for shock, hypotension or hypotension after pheochromocytoma resection due to hypovolemia
.
Sales of terminal norepinephrine bitartrate injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
The product is a national medical insurance category A variety and a basic drug variety
.
According to data from Menet.
com, in recent years , the sales of norepinephrine bitartrate injection in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly and exceeded 1 billion in 2019.
After the Yuan Dynasty, it will reach a new high in 2020, an increase of 17.
87% year-on-year
.
.
According to data from Menet.
com, in recent years , the sales of norepinephrine bitartrate injection in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly and exceeded 1 billion in 2019.
After the Yuan Dynasty, it will reach a new high in 2020, an increase of 17.
87% year-on-year
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Norepinephrine bitartrate injection production companies have lofty Pharmaceutical (China), Shandong Xinhua Pharmaceutical, Double-Crane Pharmaceutical Resources, Guangzhou Baiyunshan Mingxing pharmaceutical and other seven, which CHINAGRANDPHARM (Chinese) market share of the largest, more than 70 %, Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical ranked second and third respectively
.
.
Up to now, in terms of consistency evaluation, only Yuanda Pharmaceutical (China) has been approved as a supplementary application, and Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval
.
Hefei Yifan Biopharmaceuticals submitted listing applications in the 3 generic categories and are under review and approval.
After approval, they will be deemed to have been reviewed
.
.
Hefei Yifan Biopharmaceuticals submitted listing applications in the 3 generic categories and are under review and approval.
After approval, they will be deemed to have been reviewed
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the official website of the State Food and Drug Administration showed that Broad Pharmaceutical (China)'s norepinephrine bitartrate injection was approved as a supplementary application, making it the first company to have reviewed the product
.
According to data from Menet.
com, the sales of terminal norepinephrine bitartrate injection in public medical institutions in China have grown rapidly in recent years.
After breaking through more than 1 billion yuan in 2019, it will hit a new high in 2020
.
There are 7 manufacturers of this product.
Among them, Yuanda Pharmaceutical (China) has the largest market share, exceeding 70%
.
At present, Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval, and Hefei Yifan Biopharmaceuticals are under review and approval for listing applications submitted in generic 3 categories.
After approval, they will be deemed as over-evaluated
.
.
According to data from Menet.
com, the sales of terminal norepinephrine bitartrate injection in public medical institutions in China have grown rapidly in recent years.
After breaking through more than 1 billion yuan in 2019, it will hit a new high in 2020
.
There are 7 manufacturers of this product.
Among them, Yuanda Pharmaceutical (China) has the largest market share, exceeding 70%
.
At present, Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval, and Hefei Yifan Biopharmaceuticals are under review and approval for listing applications submitted in generic 3 categories.
After approval, they will be deemed as over-evaluated
.
Data show that norepinephrine bitartrate injection can be used to treat hypotension caused by acute myocardial infarction, cardiopulmonary bypass, etc.
, for shock, hypotension or hypotension after pheochromocytoma resection due to hypovolemia
.
, for shock, hypotension or hypotension after pheochromocytoma resection due to hypovolemia
.
Sales of terminal norepinephrine bitartrate injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
The product is a national medical insurance category A variety and a basic drug variety
.
According to data from Menet.
com, in recent years , the sales of norepinephrine bitartrate injection in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly and exceeded 1 billion in 2019.
After the Yuan Dynasty, it will reach a new high in 2020, an increase of 17.
87% year-on-year
.
.
According to data from Menet.
com, in recent years , the sales of norepinephrine bitartrate injection in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly and exceeded 1 billion in 2019.
After the Yuan Dynasty, it will reach a new high in 2020, an increase of 17.
87% year-on-year
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Norepinephrine bitartrate injection production companies have lofty Pharmaceutical (China), Shandong Xinhua Pharmaceutical, Double-Crane Pharmaceutical Resources, Guangzhou Baiyunshan Mingxing pharmaceutical and other seven, which CHINAGRANDPHARM (Chinese) market share of the largest, more than 70 %, Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical ranked second and third respectively
.
.
Up to now, in terms of consistency evaluation, only Yuanda Pharmaceutical (China) has been approved as a supplementary application, and Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval
.
Hefei Yifan Biopharmaceuticals submitted listing applications in the 3 generic categories and are under review and approval.
After approval, they will be deemed to have been reviewed
.
.
Hefei Yifan Biopharmaceuticals submitted listing applications in the 3 generic categories and are under review and approval.
After approval, they will be deemed to have been reviewed
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
A few days ago, the official website of the State Food and Drug Administration showed that Broad Pharmaceutical (China)'s norepinephrine bitartrate injection was approved as a supplementary application, making it the first company to have reviewed the product
.
According to data from Menet.
com, the sales of terminal norepinephrine bitartrate injection in public medical institutions in China have grown rapidly in recent years.
After breaking through more than 1 billion yuan in 2019, it will hit a new high in 2020
.
There are 7 manufacturers of this product.
Among them, Yuanda Pharmaceutical (China) has the largest market share, exceeding 70%
.
At present, Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval, and Hefei Yifan Biopharmaceuticals are under review and approval for listing applications submitted in generic 3 categories.
After approval, they will be deemed as over-evaluated
.
.
According to data from Menet.
com, the sales of terminal norepinephrine bitartrate injection in public medical institutions in China have grown rapidly in recent years.
After breaking through more than 1 billion yuan in 2019, it will hit a new high in 2020
.
There are 7 manufacturers of this product.
Among them, Yuanda Pharmaceutical (China) has the largest market share, exceeding 70%
.
At present, Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval, and Hefei Yifan Biopharmaceuticals are under review and approval for listing applications submitted in generic 3 categories.
After approval, they will be deemed as over-evaluated
.
Data show that norepinephrine bitartrate injection can be used to treat hypotension caused by acute myocardial infarction, cardiopulmonary bypass, etc.
, for shock, hypotension or hypotension after pheochromocytoma resection due to hypovolemia
.
, for shock, hypotension or hypotension after pheochromocytoma resection due to hypovolemia
.
Sales of terminal norepinephrine bitartrate injection in Chinese public medical institutions in recent years (unit: 100 million yuan)
Source: Terminal competition landscape of China's public medical institutions
The product is a national medical insurance category A variety and a basic drug variety
.
According to data from Menet.
com, in recent years , the sales of norepinephrine bitartrate injection in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly and exceeded 1 billion in 2019.
After the Yuan Dynasty, it will reach a new high in 2020, an increase of 17.
87% year-on-year
.
Medicine medicine medicine hospital hospital hospital.
According to data from Menet.
com, in recent years , the sales of norepinephrine bitartrate injection in urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have grown rapidly and exceeded 1 billion in 2019.
After the Yuan Dynasty, it will reach a new high in 2020, an increase of 17.
87% year-on-year
.
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
Norepinephrine bitartrate injection production companies have lofty Pharmaceutical (China), Shandong Xinhua Pharmaceutical, Double-Crane Pharmaceutical Resources, Guangzhou Baiyunshan Mingxing pharmaceutical and other seven, which CHINAGRANDPHARM (Chinese) market share of the largest, more than 70 %, Tianjin Jinyao Pharmaceutical and Shanghai Hefeng Pharmaceutical ranked second and third respectively
.
Enterprise Enterprise Enterprise Medicine Pharmaceutical Medicine.
Up to now, in terms of consistency evaluation, only Yuanda Pharmaceutical (China) has been approved as a supplementary application, and Tianjin Jinyao Pharmaceutical's supplementary application for consistency evaluation is under review and approval
.
Hefei Yifan Biopharmaceuticals submitted listing applications in the 3 generic categories and are under review and approval.
After approval, they will be deemed to have been reviewed
.
.
Hefei Yifan Biopharmaceuticals submitted listing applications in the 3 generic categories and are under review and approval.
After approval, they will be deemed to have been reviewed
.
Source: official website of the State Food and Drug Administration, Mi Nei.
com database
com database
